Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice

Neurobiology of Disease

Volumn 67, Issue , 2014, Pages 9-17

  Williams, Ian M ^a   Wallom, Kerri Lee ^a   Smith, David A ^a   Al Eisa, Nada ^a   Smith, Claire ^a   Platt, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cerebellum; Combination therapy; Curcumin; Ibuprofen; Miglustat; Neuroprotection; Niemann Pick disease type C1

Indexed keywords

CURCUMIN; IBUPROFEN; MIGLUSTAT; 1 DEOXYNOJIRIMYCIN; NEUROPROTECTIVE AGENT; NPC1 PROTEIN, MOUSE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL ACTIVATION; CELL LOSS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; MALE; MICROGLIA; MONOTHERAPY; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; PURKINJE CELL; SURVIVAL RATE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CEREBELLUM; DRUG COMBINATION; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; NIEMANN-PICK DISEASE, TYPE C; PATHOLOGY;

1-DEOXYNOJIRIMYCIN; ANIMALS; CEREBELLUM; CURCUMIN; DRUG THERAPY, COMBINATION; IBUPROFEN; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; NIEMANN-PICK DISEASE, TYPE C; PROTEINS;

EID: 84897032167     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.03.001     Document Type: Article

References (50)

1. Alvarez A.R., et al. Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J. 2008, 22(10):3617-3627.
2. Basnet P., Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011, 16:4567-4598.
3. Baudry M., et al. Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp. Neurol. 2003, 184:887-903.
4. Belcaro G., et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern. Med. Rev. 2010, 15:337-344.
5. 2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. Eur. J. Biochem. 2001, 268:6318-6327.
6. Borbon I.A., et al. Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann-Pick C1. Pharmacol. Biochem. Behav. 2012, 101:125-131.
7. Carletti B., et al. Time constraints and positional cues in the developing cerebellum regulate Purkinje cell placement in the cortical architecture. Dev. Biol. 2008, 317:147-160.
8. Davidson C.D., Walkley S.U. Niemann-Pick type C disease-pathophysiology and future perspectives for treatment. US. Neurology 2010, 6(1):88-94.
9. Davidson C.D., et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 2009, 4:e6951.
10. Elrick M.J., et al. Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum. Mol. Genet. 2010, 19:837-847.
11. Elrick M.J., et al. Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C disease. Hum. Mol. Genet. 2012, 21(22):4876-4887.
12. Estiu G., et al. Computational studies of the cholesterol transport between NPC2 and the N-terminal domain of NPC1 (NPC1(NTD)). Biochemistry 2013, 52(39):6879-6891.
13. Garver W.S., et al. The Npc1 mutation causes an altered expression of caveolin-1, annexin II and protein kinases and phosphorylation of caveolin-1 and annexin II in murine livers. Biochim. Biophys. Acta 1999, 1453(2):193-206.
14. Hovakimyan M., et al. Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice. Neuroscience 2013, 252:201-211.
15. Infante R.E., et al. NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15287-15292.
16. Ioannou Y.A. The structure and function of the Niemann-Pick C1 protein. Mol. Genet. Metab. 2000, 71:175-181.
17. Kaptzan T., et al. Development of a Rab9 transgenic mouse and its ability to increase the lifespan of a murine model of Niemann-Pick type C disease. Am. J. Pathol. 2009, 174(1):14-20.
18. Ko D.C., et al. Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease. PLoS Genet. 2005, 1:81-95.
19. Kozlowski C., Weimer R.M. An automated method to quantify microglia morphology and application to monitor activation state longitudinally in vivo. PLoS One 2012, 7:e31814.
20. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
21. Kwon H.J., et al. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 2009, 137(7):1213-1224.
22. -/- mouse. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2377-2382.
23. Lloyd-Evans E., Platt F.M. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic 2010, 11:419-428.
24. Lloyd-Evans E., et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 2008, 14:1247-1255.
25. Lopez M.E., et al. Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder. J. Neurosci. 2011, 31:4367-4378.
26. Lopez M.E., et al. Neuronal and epithelial cell rescue resolves chronic systemic inflammation in the lipid storage disorder Niemann-Pick C. Hum. Mol. Genet. 2012, 21:2946-2960.
27. Lopresti A.L., et al. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J. Psychopharmacol. 2012, 26:1512-1524.
28. Madra M., Sturley S.L. Niemann-Pick type C pathogenesis and treatment: from statins to sugars. Clin. Lipidol. 2010, 5(3):387-395.
29. Munkacsi A.B., et al. An "exacerbate-reverse" strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease. J. Biol. Chem. 2011, 286:23842-23851.
30. Patterson M.C., et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007, 6:765-772.
31. Patterson M.C., et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol. Genet. Metab. 2012, 106:330-344.
32. Pentchev P.G., et al. A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase. Biochim. Biophys. Acta 1980, 619:669-679.
33. Pipalia N.H., et al. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5620-5625.
34. Platt F.M., et al. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 1994, 269:8362-8365.
35. Raivich G., et al. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Brain Res. Rev. 1999, 30:77-105.
36. Sarkar S., et al. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease. Cell Rep. 2013, 5(5):1302-1315.
37. Sarna J.R., et al. Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease. J. Comp. Neurol. 2003, 456:279-291.
38. Smith D., et al. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol. Dis. 2009, 36:242-251.
39. Srivastava R.M., et al. Immunomodulatory and therapeutic activity of curcumin. Int. Immunopharmacol. 2011, 11:331-341.
40. Storch J., Xu Z. Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim. Biophys. Acta 2009, 1791:671-678.
41. te Vruchte D., et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. J. Biol. Chem. 2004, 279:26167-26175.
42. Vanier M.T. Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem. Res. 1999, 24:481-489.
43. Vanier M.T. Niemann-Pick disease type C. Orphanet J. Rare Dis. 2010, 5:16.
44. Vanier M.T., et al. Type C Niemann-Pick disease: biochemical aspects and phenotypic heterogeneity. Dev. Neurosci. 1991, 13:307-314.
45. Wada R., et al. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10954-10959.
46. Walter M., et al. Endosomal lipid accumulation in NPC1 leads to inhibition of PKC, hypophosphorylation of vimentin and Rab9 entrapment. Biol. Cell. 2009, 101(3):141-152.
47. Williams I.M., et al. Cerebellar granule cells transplanted in vivo can follow physiological and unusual migratory routes to integrate into the recipient cortex. Neurobiol. Dis. 2008, 30:139-149.
48. Wraith J.E., et al. Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol. Genet. Metab. 2009, 98:152-165.
49. Yu T., et al. Temporal and cell-specific deletion establishes that neuronal Npc1 deficiency is sufficient to mediate neurodegeneration. Hum. Mol. Genet. 2011, 20:4440-4451.
50. Zervas M., et al. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr. Biol. 2001, 11:1283-1287.